Reach Unveils Major Expansion Initiative
Reach Separations is set to double laboratory space at its UK-based facility as a result of increased demand for its specialist purification services.
The expansion will see significant investment in analytical equipment and purification systems and at the company’s headquarters located at BioCity in Nottingham.
Growth for the purification expert is being driven by increased demand for its chromatography capabilities from the drug discovery, contract research and agrochemical sectors across Europe.
With a focus on providing purification with a rapid turnaround time to ensure the material is in back in the hands of the chemist quickly, Reach Separations has built a reputation for being one of the most sophisticated chromatography purification providers in the contract services space.
The company’s technical group is led by director Phil Abbott, who has worked in the pharmaceutical industry for over 20 years, including several years at AstraZeneca as a Separation Science Group Leader. He said: “This venture is a major milestone for our organisation and essentially enables us to do more of what we’ve already been doing over the last few years, but at even greater speed for even more customers.
“Our clients typically require purified materials as quickly as possible. Our expanded resource and capacity will allow us to work at increased speed to help reduce screen time and get compounds back to clients even quicker, helping meet tight deadlines.
“The upsurge in demand we have experienced from companies developing new compounds shows no sign of slowing down so its important that we are proactive about expansion and ready to meet the needs of new and existing clients.”
The company’s accelerated growth has also been bolstered by a thriving strategic alliance with Evotec, which has seen the company support the CRO in helping hit client deadlines on a consistent basis. After becoming a technology partner in 2014, Reach Separations has since provided ongoing purification, analytical and small molecule chromatography to aid Evotec’s pharmaceutical and biotech clients worldwide.
Supporting small molecule synthesis requirements, the company supports clients in the fields of chiral, reverse phase and normal phase chromatography from mg scale to in excess of 500 g.
“Adding a UPC2, QDa Mass spectrometry detector, HClass UPLC, rotary evaporators and two preparative SFCs will massively enhance our offering to the market. “For instance, the new equipment will allow us to use SFC with mass spectrometry, which is a very rare technique to see in the sector so is an exciting capability addition,” added Mr Abbott.
Reach Separations recently joined a UK-led CRO mission to Scandinavia to present how collaborative outsourcing can help drug development companies overcome R&D scientific challenges.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance